2023 was a tough yr to the biopharma industry, with quite a few firms downsizing and restructuring their workforces to remain afloat. There are actually signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and lifetime sciences business from the latter part of 2023 and have continued https://sites.google.com/view/bio-sites/blog